AC676-001 is a Phase I, first-in-human, open-label, multi-center dose-escalation study of AC676 given as a single agent. AC676 is an investigational medicinal product that is an orally bioavailable BTK degrader for the treatment of B-cell malignancies.
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to:~Identify the recommended dose of AC676 that can be given safely to participants~Evaluate the safety profile of AC676~Evaluate the pharmacokinetics of AC676~Evaluate the effectiveness of AC676